Biocon has 2024 as the year of transition as the acquire viatris business. THE YOY numbers are not comparable so these Sales and EBITDA comparisons are not relevant, and they don’t produce x viatris numbers because it was not a truly separate business, rather a marketing and front office and client owner as product owner and Biocon was a contract manufacture partner.
PAT is also lower because of one time REBATE in US for Viatris client contact with a managed service provider for USD 20 M /INR 170 CR
| Subscribe To Our Free Newsletter |
